Department of Veterinary Internal Medicine, College of Veterinary Medicine, Seoul National University, Seoul, Republic of Korea.
KPC Corporation, Oporo, Gwangju, Republic of Korea.
In Vivo. 2019 Sep-Oct;33(5):1455-1461. doi: 10.21873/invivo.11624.
BACKGROUND/AIM: Idiopathic pulmonary fibrosis (PF) is a fatal disorder of unknown aetiology with limited treatment options. Chitosan has antibacterial, antifungal, antioxidant, antitumour, and anti-inflammatory effects. This study aimed to investigate the effects of chitosan administration on bleomycin (BLM)-induced PF in rats.
A PF rat model was established by endotracheal instillation of 5 mg/kg BLM; then, chitosan was administered in drinking water for 3 weeks. Histology, cell counts, and cytokine responses in the bronchoalveolar lavage fluid (BALF) and weight measurements (body and lung) were analyzed to assess its therapeutic effects.
Chitosan administration tended to reduce transforming growth factor (TGF)-β1 and interferon (IFN)-γ levels in BALF, and histopathological examination confirmed that chitosan attenuated the degree of inflammation and fibrosis in the lung.
This study revealed that oral chitosan exhibits potential antifibrotic effects, as measured by decreased proinflammatory cytokine levels and histological evaluation, in a BLM-induced PF rat model.
背景/目的：特发性肺纤维化（PF）是一种病因不明的致命疾病，治疗选择有限。壳聚糖具有抗菌、抗真菌、抗氧化、抗肿瘤和抗炎作用。本研究旨在探讨壳聚糖给药对博莱霉素（BLM）诱导的 PF 大鼠的影响。
通过气管内滴注 5mg/kg BLM 建立 PF 大鼠模型；然后，壳聚糖在饮用水中给药 3 周。通过分析支气管肺泡灌洗液（BALF）中的组织学、细胞计数和细胞因子反应以及体重测量（体质量和肺质量）来评估其治疗效果。
壳聚糖给药可降低 BALF 中的转化生长因子（TGF）-β1 和干扰素（IFN）-γ水平，组织病理学检查证实壳聚糖可减轻肺的炎症和纤维化程度。
本研究表明，口服壳聚糖通过降低促炎细胞因子水平和组织学评估，在 BLM 诱导的 PF 大鼠模型中显示出潜在的抗纤维化作用。
